

## QIBA PET-Amyloid Biomarker Committee (BC) Call

11 January 2019 at 9:00 AM CT

Call Summary

*Notes provided by Ms. Matthews and supplemented by RSNA Staff*

### In attendance:

*Dawn Matthews, MS, MBA (Co-Chair)*

*Anne Smith, PhD (Co-Chair)*

*Satoshi Minoshima, MD (Co-Chair)*

Bing Bai, PhD

Rachid Fahmi, MSc, PhD

Eric Perlman, MD

### RSNA

Joe Koudelik

Julie Lisiecki

**Moderator:** Ms. Matthews

### RSNA 2018 Recap:

- Break out session discussion at the QIBA f2f Working Meeting focused on the draft questionnaire for volunteer sites re: Profile feasibility testing

### Next targets:

- The next target is achieving technical confirmation
- The conformance process must be finalized and confirmed
- Decisions on making use of this work need to be made

### Technical Confirmation Discussion Outputs:

- Sites have been identified
- Need to consolidate and reduce questions to be logistically feasible to complete
  - Extracting items specific to site personnel and those already implemented for ADNI would save participants time
  - Consolidating other questions will also be helpful
  - A phone or tablet accessible survey format could facilitate response
  - Modifications are required in order to be applicable for EU users

### Technical Confirmation Status:

- Extraction of items specific to sites and reclassifying the actor for three items reduced the number of items from 167 to 68
- Grouping of ADNI compliant items consolidated 23 of the items, leaving 45 items for additional review
- [SurveyMonkey](#) was suggested for the questionnaire platform, as it is very user-friendly

### Next Steps:

- Group ADNI items but retain for verification and reference
- Consolidate the 45 items where feasible, targeting 20 questions as the goal limit
- Obtain responses – need representative to coordinate responses
- Modifications are needed for the European version of the Profile
  - Dr. Lammertsma has agreed to help
- Other sections that do not relate to the ADNI protocol include:
  - Image analysis
  - Scanner manufacturers

### Overall direction:

- The BC wants to get to the next Profile milestone of Technically Confirmed
- This will be accomplished by:
  - Utilizing the responses to questionnaires
  - Completing and verifying the conformance section
  - Communicating with volunteer participants and incorporating any additional feedback

**Other topics:**

- Dr. Smith reminded the group that Dr. Kinahan's amyloid DRO work will also be a vital part of this effort once it is complete, as this will be used for conformance testing
- Dr. Kinahan requested to present the latest amyloid DRO on an upcoming BC call

**QIBA Nuclear Medicine Schedule:**  
-----

The next scheduled QIBA calls will be as follows at **9 am CT** unless otherwise noted:

<b>1/15/2019</b>	SPECT BC: TC <sup>99m</sup> @ 2pm CT
<b>1/25/2019</b>	NM Leadership - <b>TBD</b>
<b>2/1/2019</b>	FDG-PET BC
<b>2/8/2019</b>	PET Amyloid BC
<b>2/12/2019</b>	SPECT BC: TC <sup>99m</sup> @ 2pm CT
<b>2/15/2019</b>	I-123 BC - <b>TBD</b>
<b>2/22/2019</b>	<b>Hold for NM Coordinating Committee</b>